Lupus Science & Medicine
42 Cody EM, Wenderfer SE, Sullivan KE, et al . Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatr Nephrol 2023;38:2679–88. 43 Gupta R, Yadav A, Aggarwal A. Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity. Clin Rheumatol 2016;35:2707–14. 44 Parodis I, Gokaraju S, Zickert A, et al . ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford ) 2020;59:2237–49. 45 Malvar A, Pirruccio P, Alberton V, et al . Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 2017;32:1338–44. 46 Makhammajanov Z, Gaipov A, Myngbay A, et al . Tubular toxicity of proteinuria and the progression of chronic kidney disease. Nephrol Dial Transplant 2024;39:589–99. 47 Korbet SM, Lewis EJ, Schwartz MM, et al . Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000;35:904–14. 48 Arazi A, Rao DA, Berthier CC, et al . The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 2019;20:902–14. 49 Davidson A. Renal Mononuclear Phagocytes in Lupus Nephritis. ACR Open Rheumatol 2021;3:442–50. 50 Chen W, Jin B, Cheng C, et al . Single-cell profiling reveals kidney CD163 + dendritic cell participation in human lupus nephritis. Ann Rheum Dis 2024;83:608–23. 51 Haller H, Bertram A, Nadrowitz F, et al . Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens 2016;25:42–9. 52 Deshmane SL, Kremlev S, Amini S, et al . Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313–26. 53 Rovin BH, Song H, Hebert LA, et al . Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 2005;68:1825–33. 54 Dini AA, Wang P, Ye DQ. Serum Adiponectin Levels in Patients With Systemic Lupus Erythematosus: A Meta-analysis. J Clin Rheumatol 2017;23:361–7. 55 Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti- atherogenic properties of adiponectin. Biochimie 2012;94:2137–42. 56 Rutkowski JM, Wang ZV, Park ASD, et al . Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013;24:268–82. 57 Chedid P, Hurtado-Nedelec M, Marion-Gaber B, et al . Adiponectin and its globular fragment differentially modulate the oxidative burst of primary human phagocytes. Am J Pathol 2012;180:682–92. 58 Choi H-M, Lee Y-A, Lee S-H, et al . Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009;11:R161. 59 Lee Y-A, Ji H-I, Lee S-H, et al . The role of adiponectin in the production of IL-6, IL-8, VEGF and MMPs in human endothelial cells and osteoblasts: implications for arthritic joints. Exp Mol Med 2014;46:e72. 60 Lee Y-A, Choi HM, Lee S-H, et al . Synergy between adiponectin and interleukin-1 β on the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in fibroblast-like synoviocytes. Exp Mol Med 2012;44:440–7. 61 Sammaritano LR, Askanase A, Bermas BL, et al . 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care Res (Hoboken) 2025;77:1045–65. 62 Whittall-Garcia L, Baker R, Kim M, et al . UTILITY OF URINARY BIOMARKERS TO PREDICT LONG-TERM RENAL OUTCOMES IN LUPUS NEPHRITIS. J Rheumatol 2025;52:43.
21 Illei GG, Takada K, Parkin D, et al . Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995–1002. 22 Furie R, Rovin BH, Houssiau F, et al . Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020;383:1117–28. 23 Whittall Garcia LP, Gladman DD, Urowitz M, et al . Interferon- α as a biomarker to predict renal outcomes in lupus nephritis. Lupus Sci Med 2024;11:e001347. 24 Chen Y, Huang S, Chen T, et al . Machine Learning for Prediction and Risk Stratification of Lupus Nephritis Renal Flare. Am J Nephrol 2021;52:152–60. 25 Rijnink EC, Teng YKO, Wilhelmus S, et al . Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. Clin J Am Soc Nephrol 2017;12:734–43. 26 Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515–26. 27 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36. 28 McGee S. Simplifying likelihood ratios. J Gen Intern Med 2002;17:646–9. 29 Cooper Blenkinsopp S, Fu Q, Green Y, et al . Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort. Lupus Sci Med 2022;9:e000598. 30 Davidson JE, Fu Q, Ji B, et al . Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. J Rheumatol 2018;45:671–7. 31 Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares--an update. Nat Rev Nephrol 2012;8:709–17. 32 Ngamjanyaporn P, Worawichawong S, Pisitkun P, et al . Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios. PLoS One 2022;17:e0263778. 33 Mok CC, Soliman S, Ho LY, et al . Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. Arthritis Res Ther 2018;20:6. 34 Soliman S, Mohamed FA, Ismail FM, et al . Urine angiostatin and VCAM-1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis. Int J Rheum Dis 2017;20:1714–27. 35 Stanley S, Vanarsa K, Soliman S, et al . Comprehensive aptamer- based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nat Commun 2020;11:2197. 36 Soliman SA, Haque A, Vanarsa K, et al . Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus. Front Immunol 2022;13:885307. 37 Endo N, Tsuboi N, Furuhashi K, et al . Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant 2016;31:2023–33. 38 Fava A, Buyon J, Magder L, et al . Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 2024;9:e172569. 39 Renaudineau Y, Chauveau D, Faguer S, et al . Urinary soluble CD163 is useful as “liquid biopsy” marker in lupus nephritis at both diagnosis and follow-up to predict impending flares. J Transl Autoimmun 2024;9:100244. 40 Zhang T, Li H, Vanarsa K, et al . Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. Front Immunol 2020;11:671. 41 Brunner HI, Bennett MR, Gulati G, et al . Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. J Rheumatol 2017;44:1239–48.
12
Baker R, et al . Lupus Science & Medicine 2026; 13 :e001724. doi:10.1136/lupus-2025-001724
Powered by FlippingBook